Passage BIO, Inc. (PASG) company profile
Close on Nov 13, 2026Market cap $13.68MP/E –Yield –
About Passage BIO
Biological Products, (No Diagnostic Substances), SIC 2836
Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases of the central nervous system. The company specializes in one-time adeno-associated virus (AAV) gene therapies designed to address underlying disease pathologies. Its lead product candidate is PBFT02, a gene replacement therapy delivered via intra cisterna magna administration to elevate progranulin levels. PBFT02 is in clinical trials for frontotemporal dementia caused by progranulin deficiency and frontotemporal dementia associated with C9orf72 mutations, with potential application in amyotrophic lateral sclerosis and Alzheimer’s disease. Additionally, the company conducts a preclinical program targeting Huntington’s disease.
The company operates internationally, conducting its upliFT-D clinical trial across multi-center global sites. Preclinical and clinical development activities are supported through collaborations in the United States, including partnerships with Gemma Biotherapeutics and outsourced manufacturing relationships with Catalent in Maryland. Passage Bio's operations and pipeline development focus on patient populations in the United States and Europe.
Summary of the business section of Passage BIO's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Passage BIO, Inc.
- Headquarters
- Philadelphia, PA
- Address
- One Commerce Square, 2005 Market Street, 39th Floor 19103
- Phone
- (267) 866-0312
- Website
- passagebio.com
- Employees
- 24, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Philadelphia, PA
Stock & identifiers
- Ticker
- PASG
- Exchange
- Nasdaq
- IPO date
- Feb 28, 2020
- Shares outstanding
- 3M, Aug 5, 2026
- Public float
- $25.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-19.5 reverse, Aug 12, 2025; 1-for-20 reverse, Jul 14, 2025
- SEC CIK
- 1787297
- CUSIP
- 702712209
- ISIN
- US7027122099
- FIGI
- BBG00NBK4XF9
- Share class FIGI
- BBG00NBK4XG8
- EIN
- 82-2729751
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Chou | PRESIDENT AND CEO, Director | 6,524 |
| Kathleen Borthwick | CFO | 5,402 |
| Edgar B. Cale | GC & CORPORATE SECRETARY | 45,995 |
| Athena Countouriotis | Director | 18,900 |
| Derrell Porter | Director | – |
| Thomas Richard Kassberg | Director | – |
| Maxine Gowen | Director | – |
| Sandip Kapadia | Director | 0 |
| Dolan Sondhi | Director | – |
| Saqib Islam | Director | 5,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.49M | $1.53M | $722.57K | $58 | – |
| FY2024 | $1.64M | $902.53K | $871.81K | $56 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| William Chou, M.D. President, Chief Executive Officer and Director | $660.99K | $234.04K | $239.27K | $334.97K | $17.50K | $1.49M | -9% |
| Kathleen Borthwick Chief Financial Officer | $450.63K | $117.02K | $85.44K | $181.25K | $17.50K | $851.84K | -1% |
| Edgar B. (Chip) Cale General Counsel and Corporate Secretary | $221.86K | $197.08K | $156.85K | – | $17.50K | $593.29K | -33% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 28, 2020
- Offer price
- $18.00
- Securities offered
- 12,000,000
- Gross proceeds
- $216.00M
- Exchange
- Nasdaq
- First trading day
- Feb 28, 2020
- First-day close
- $22.20+23.3%
- Lock-up ends (est.)
- Aug 26, 2020
“The initial public offering price is $18.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 24 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 21, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jan 31, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 2, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 1, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 18, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?